Renaissance Capital logo

NBRV News

US IPO Weekly Recap: Health care goes three for three as IPOs trade up 30%

PEN

When there's trouble in the markets, IPO investors can rely on unprofitable, early-stage health care companies. The IPO market ended its annual end-of-summer lull as ...read more

Nabriva Therapeutics prices IPO at $10.25, below downwardly revised expectations

Nabriva Therapeutics logo

Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, raised $92 million by offering 9 million ADSs at $10.25, below the downwardly revised price of $10.50. The company originally planned to offer 6 million ADSs at $15 to $17....read more

Anti-antibiotic biotech: Nabriva Therapeutics lowers proposed price to $10.50 ahead of IPO

Nabriva Therapeutics logo

Nabriva Therapeutics, which is developing a novel antibiotic for bacterial pneumonia, lowered the proposed offer price ahead of its upcoming IPO on Thursday. The Vienna, Austria-based company now plans to raise $95 million by offering 9.0 million ADSs at...read more

Week ahead: 3 health care IPOs set to price during the week of September 14

Nabriva Therapeutics logo

After three weeks without any deals, the US IPO market is back in session. Three health care companies are each set to raise about $100 million in the week ahead....read more